CAIMH
REGN icon

Central Asset Investments & Management Holdings’s Regeneron Pharmaceuticals REGN Stock Holding History

Central Asset Investments & Management Holdings’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-400
Closed -$242K – 74
2021
Q3 		$242K Buy
+400
New +$248K 0.13% 61

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Central Asset Investments & Management Holdings's REGN Position: Q4 2021 in Review

Central Asset Investments & Management Holdings sold out of Regeneron Pharmaceuticals (REGN) in Q4 2021, closing a stake of 400 shares — an estimated $242K sold.

Central Asset Investments & Management Holdings first reported a position in REGN in Q3 2021 and held it in 1 quarter. The position peaked at $242K in Q3 2021. 1,080 funds tracked by Wall St. Rank hold REGN as of Q4 2021.

  • Central Asset Investments & Management Holdings reported no remaining Regeneron Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Central Asset Investments & Management Holdings sold 400 Regeneron Pharmaceuticals shares in Q4 2021, an estimated $242K.
  • Central Asset Investments & Management Holdings first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Central Asset Investments & Management Holdings's Regeneron Pharmaceuticals position peaked at $242K in Q3 2021.
  • 1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2021.

Based on Central Asset Investments & Management Holdings's 13F filing for Q4 2021, filed 11 Feb 2022.